These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38340237)

  • 1. The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.
    Burshtein J; Shah M; Zakria D; Lockshin B; Crowley J; Merola JF; Gordon K; Shahriari M; Korman NJ; Chovatiya R; Kalb R; Lebwohl M
    Dermatol Ther (Heidelb); 2024 Feb; 14(2):323-339. PubMed ID: 38340237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.
    Burshtein J; Shah M; Zakria D; Armstrong AW; Golant AK; Gottlieb AB; Weinberg JM; Kircik L; Han G; Langley RG; Neimann AL; Lebwohl M
    J Drugs Dermatol; 2024 Aug; 23(8):592-599. PubMed ID: 39093660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating a Prognostic Gene Expression Profile Test into the Management of Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel Report.
    Zakria D; Brownstone N; Berman B; Ceilley R; Cronin TA; Del Rosso JQ; Ferris LK; Goldenberg G; Siegel D
    J Drugs Dermatol; 2023 Dec; 22(12):7691. PubMed ID: 38051842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporating a Prognostic Gene Expression Profile Test into the Management of Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel Report.
    Zakria D; Brownstone N; Berman B; Ceilley R; Cronin TA; Del Rosso JQ; Ferris LK; Goldenberg G; Siegel D
    J Drugs Dermatol; 2024 Feb; 23(2):54-60. PubMed ID: 38306124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in Technology for Melanoma Diagnosis and Prognosis: An Expert Consensus Panel.
    Burshtein J; Zakria D; Shah M; Berman B; Desai SR; Farberg AS; Goldenberg G; Glick B; Nestor M; Nouri K; Rosen T; Lebwohl M; Rigel D
    J Drugs Dermatol; 2024 Sep; 23(9):774-781. PubMed ID: 39231082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis.
    Ali Z; Matthews R; Al-Janabi A; Warren RB
    Expert Rev Clin Immunol; 2021 Oct; 17(10):1073-1081. PubMed ID: 34384327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation.
    Ruggiero A; Potestio L; Martora F; Villani A; Comune R; Megna M
    Expert Opin Drug Saf; 2023; 22(5):355-362. PubMed ID: 37222656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
    Merola JF; Landewé R; McInnes IB; Mease PJ; Ritchlin CT; Tanaka Y; Asahina A; Behrens F; Gladman DD; Gossec L; Gottlieb AB; Thaçi D; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Coates LC
    Lancet; 2023 Jan; 401(10370):38-48. PubMed ID: 36495881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bimekizumab for the treatment of psoriatic disease.
    Natsis NE; Gottlieb AB
    Expert Opin Biol Ther; 2018 Dec; 18(12):1193-1197. PubMed ID: 30332893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives.
    Camiña-Conforto G; Mateu-Arrom L; López-Ferrer A; Puig L
    Patient Prefer Adherence; 2023; 17():1541-1549. PubMed ID: 37408843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
    Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
    J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis.
    Reis J; Vender R; Torres T
    BioDrugs; 2019 Aug; 33(4):391-399. PubMed ID: 31172372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bimekizumab-bkzx for the Treatment of Plaque Psoriasis: A Drug Review.
    Greer ME; Moran SK; Feldman SR
    Ann Pharmacother; 2024 Oct; ():10600280241288553. PubMed ID: 39425925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
    Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A
    Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bimekizumab for psoriasis.
    Rodrigues MA; Freitas E; Torres T
    Drugs Today (Barc); 2022 Jun; 58(6):273-282. PubMed ID: 35670705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.
    Oliver R; Krueger JG; Glatt S; Vajjah P; Mistry C; Page M; Edwards H; Garcet S; Li X; Dizier B; Maroof A; Watling M; El Baghdady A; Baeten D; Ionescu L; Shaw S
    Br J Dermatol; 2022 Apr; 186(4):652-663. PubMed ID: 34687214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
    McInnes IB; Asahina A; Coates LC; Landewé R; Merola JF; Ritchlin CT; Tanaka Y; Gossec L; Gottlieb AB; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Mease PJ
    Lancet; 2023 Jan; 401(10370):25-37. PubMed ID: 36493791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
    Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.